Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties

Objectives: Erlotinib HCl is a tyrosine kinase receptor inhibitor and an anticancer agent that was first approved by the FDA in 2004 for treatment of non-small-cell lung cancer and pancreatic cancer. Dexketoprofen trometamol is a NSAID, but recent studies showed that dexketoprofen trometamol also had an effect in carcinoma due to its inhibitor effects on prostaglandins. The combination of dexketoprofen and anti-cancer agents reduces pain caused by cancer by diminishing the tumors pressure, which causes necrosis; it also lowers the poor prognosis of cancer. Combination therapy will make life easier for patients, considering drug administration and dosing. Nanocochleates are new drug delivery systems that have not been examined as much as liposomes, but they have more advantages than liposomes.